We are live on ! Find out more
CORT icon

Corcept Therapeutics

80 hedge funds and large institutions have $244M invested in Corcept Therapeutics in 2015 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 37 increasing their positions, 16 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

27,467% more call options, than puts

Call options by funds: $2.48M | Put options by funds: $9K

267% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 6

131% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 16

25% more funds holding

Funds holding: 6480 (+16)

14% more capital invested

Capital invested by funds: $215M → $244M (+$29.8M)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

Holders
80
Holders Change
+16
Holders Change %
+25%
% of All Funds
2.14%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
22
Increased
37
Reduced
16
Closed
6
Calls
$2.48M
Puts
$9K
Net Calls
+$2.47M
Net Calls Change
+$2.46M

CORT Hedge Fund Activity: Q2 2015 in Review

80 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q2 2015, worth a combined $244M — up 14% from $215M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new CORT positions and 6 closed out — a net gain of 16 holders — while 37 added to existing stakes and 16 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $2.74M. The largest seller was Investor AB, cutting an estimated $8.23M.

  • 80 institutional investors held Corcept Therapeutics (CORT) as of Q2 2015, up from 64 in Q1 2015.
  • Funds reported $244M of Corcept Therapeutics stock for Q2 2015, up 14% quarter-over-quarter.
  • 22 funds opened new Corcept Therapeutics positions in Q2 2015 and 6 closed out, a net change of +16 holders.
  • The largest Corcept Therapeutics buyer in Q2 2015 was Renaissance Technologies, an estimated $2.74M added.
  • The largest Corcept Therapeutics seller in Q2 2015 was Investor AB, an estimated $8.23M sold.

Based on aggregated 13F filings for Q2 2015.